Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00617669
Registration number
NCT00617669
Ethics application status
Date submitted
24/01/2008
Date registered
18/02/2008
Date last updated
10/09/2012
Titles & IDs
Public title
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
Query!
Scientific title
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 (Zibotentan) in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer
Query!
Secondary ID [1]
0
0
D4320C00033
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ENTHUSE M1C
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Docetaxel
Treatment: Drugs - ZD4054
Treatment: Drugs - Placebo
Active Comparator: Placebo + Docetaxel - placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
Experimental: ZD4054 + Docetaxel - ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
Treatment: Drugs: Docetaxel
intravenous infusion given every three weeks
Treatment: Drugs: ZD4054
10 mg oral once daily dose
Treatment: Drugs: Placebo
placebo oral tablet once daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Median time (in months) from randomisation until death using the Kaplan-Meier method.
Query!
Timepoint [1]
0
0
Patients were followed for survival up to 40 months
Query!
Secondary outcome [1]
0
0
Progression Free Survival
Query!
Assessment method [1]
0
0
Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method. Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline
Query!
Timepoint [1]
0
0
Patients were followed for progression up to 40 months
Query!
Secondary outcome [2]
0
0
Incidence of Skeletal Related Events
Query!
Assessment method [2]
0
0
Median time (in months) from randomisation until occurrence of a skeletal related event using the Kaplan-Meier method, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression.
Query!
Timepoint [2]
0
0
While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Query!
Secondary outcome [3]
0
0
Time to Prostate-specific Antigen (PSA) Progression
Query!
Assessment method [3]
0
0
Median time (in months) from randomisation until first PSA value >50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.
Query!
Timepoint [3]
0
0
While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Query!
Secondary outcome [4]
0
0
Time to Pain Progression
Query!
Assessment method [4]
0
0
Median time (in months) from randomisation until date of first assessment of increased pain using the Kaplan-Meier method, where increased pain event is defined as the first of a patient requiring opiate medication for duration of =1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.
Query!
Timepoint [4]
0
0
While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Query!
Secondary outcome [5]
0
0
Pain Response
Query!
Assessment method [5]
0
0
Number of patients with a pain response, defined as a decrease in brief pain inventory questionnaire (BPI) of at least 2 points from baseline or a decrease in opiate use of 25% from baseline.
Query!
Timepoint [5]
0
0
While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Query!
Secondary outcome [6]
0
0
Health Related Quality of Life
Query!
Assessment method [6]
0
0
Median time (in months) from randomisation until deterioration of Health Related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.
Query!
Timepoint [6]
0
0
While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Query!
Secondary outcome [7]
0
0
PSA Response
Query!
Assessment method [7]
0
0
PSA response defined as >50% decrease in serum PSA values from baseline seen in at least 2 consecutive PSA values at least 2 weeks apart.
Query!
Timepoint [7]
0
0
While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Query!
Eligibility
Key inclusion criteria
Patients who answer TRUE to the following criteria may be eligible to participate in this
trial.
- Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has
spread to the bone (bone metastasis)
- Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment
- Currently receiving treatment with surgical or medical castration
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients who answer TRUE to the following ARE NOT eligible to participate in this trial.
- Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior
targeted cancer therapies are permitted if received during a previous clinical trial.
- Suffering from heart failure or had a myocardial infarction within last 6 months
- A history of epilepsy or seizures
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1494
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Research Site - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Research Site - St Leonards
Query!
Recruitment hospital [3]
0
0
Research Site - Wollongong
Query!
Recruitment hospital [4]
0
0
Research Site - Redcliffe
Query!
Recruitment hospital [5]
0
0
Research Site - Ashford
Query!
Recruitment hospital [6]
0
0
Research Site - Footscray
Query!
Recruitment hospital [7]
0
0
Research Site - Wodonga
Query!
Recruitment hospital [8]
0
0
Research Site - Perth
Query!
Recruitment hospital [9]
0
0
Research Site - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
- Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
- St Leonards
Query!
Recruitment postcode(s) [3]
0
0
- Wollongong
Query!
Recruitment postcode(s) [4]
0
0
- Redcliffe
Query!
Recruitment postcode(s) [5]
0
0
- Ashford
Query!
Recruitment postcode(s) [6]
0
0
- Footscray
Query!
Recruitment postcode(s) [7]
0
0
- Wodonga
Query!
Recruitment postcode(s) [8]
0
0
- Perth
Query!
Recruitment postcode(s) [9]
0
0
- Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nebraska
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
South Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Tennessee
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Virginia
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Washington
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Wisconsin
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Buenos Aires
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Santa Fe
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Ceara/ LA
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
Goias/ LA
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Goias
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Minas GERMANYais
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Parana/ Brazil
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
PR
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Rio Grande do Sul/ LA
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
RJ
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Sao Paulo/ LA
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Sao Paulo
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Manitoba
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Nova Scotia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Ontario
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Quebec
Query!
Country [33]
0
0
Czech Republic
Query!
State/province [33]
0
0
CZECHOSLOVAKIA Republic
Query!
Country [34]
0
0
Czech Republic
Query!
State/province [34]
0
0
Jablonec nad Nisou
Query!
Country [35]
0
0
Czech Republic
Query!
State/province [35]
0
0
Kromeriz
Query!
Country [36]
0
0
Czech Republic
Query!
State/province [36]
0
0
Olomouc
Query!
Country [37]
0
0
Czech Republic
Query!
State/province [37]
0
0
Prague 2
Query!
Country [38]
0
0
Czech Republic
Query!
State/province [38]
0
0
Prague 6
Query!
Country [39]
0
0
Czech Republic
Query!
State/province [39]
0
0
Usti nad Labem
Query!
Country [40]
0
0
Finland
Query!
State/province [40]
0
0
Helsinki
Query!
Country [41]
0
0
Finland
Query!
State/province [41]
0
0
Joensuu
Query!
Country [42]
0
0
Finland
Query!
State/province [42]
0
0
Seinajoki
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
FRANCEnce
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Paris
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Saint Herblain
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
GERMANYmany
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Berlin
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Bonn
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Dresden
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Emmendingen
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Kirchheim-Teck
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Leipzig
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Luebeck
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Muenster
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Tuebingen
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Wuppertal
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
HUNGARYary
Query!
Country [58]
0
0
India
Query!
State/province [58]
0
0
Karnataka
Query!
Country [59]
0
0
India
Query!
State/province [59]
0
0
Kerala
Query!
Country [60]
0
0
India
Query!
State/province [60]
0
0
Madhya Pradesh
Query!
Country [61]
0
0
India
Query!
State/province [61]
0
0
Maharashtra
Query!
Country [62]
0
0
India
Query!
State/province [62]
0
0
Rajasthan
Query!
Country [63]
0
0
India
Query!
State/province [63]
0
0
Tamil Nadu
Query!
Country [64]
0
0
India
Query!
State/province [64]
0
0
West Bengal
Query!
Country [65]
0
0
India
Query!
State/province [65]
0
0
Delhi
Query!
Country [66]
0
0
India
Query!
State/province [66]
0
0
New Delhi
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Genoa
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Lugo (RA)
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Rome
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Chungbuk
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Gyeonggi-do
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Seoul
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
Nijmegen
Query!
Country [74]
0
0
Peru
Query!
State/province [74]
0
0
Arequipa
Query!
Country [75]
0
0
Peru
Query!
State/province [75]
0
0
Callao
Query!
Country [76]
0
0
Peru
Query!
State/province [76]
0
0
Lima
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
POLANDand
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Koscierzyna
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Wroclaw
Query!
Country [80]
0
0
Portugal
Query!
State/province [80]
0
0
PORTUGALtugal
Query!
Country [81]
0
0
Romania
Query!
State/province [81]
0
0
Bucharest
Query!
Country [82]
0
0
Romania
Query!
State/province [82]
0
0
Sibiu
Query!
Country [83]
0
0
Romania
Query!
State/province [83]
0
0
Timisoara
Query!
Country [84]
0
0
Russian Federation
Query!
State/province [84]
0
0
RUSSIAsia
Query!
Country [85]
0
0
Serbia
Query!
State/province [85]
0
0
SERBIAbia
Query!
Country [86]
0
0
South Africa
Query!
State/province [86]
0
0
Cape Town
Query!
Country [87]
0
0
South Africa
Query!
State/province [87]
0
0
Durban
Query!
Country [88]
0
0
South Africa
Query!
State/province [88]
0
0
Bloemfontein
Query!
Country [89]
0
0
South Africa
Query!
State/province [89]
0
0
PORt Elizabeth
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Madrid
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Valencia
Query!
Country [92]
0
0
Sweden
Query!
State/province [92]
0
0
Stockholm
Query!
Country [93]
0
0
Sweden
Query!
State/province [93]
0
0
Uppsala
Query!
Country [94]
0
0
Switzerland
Query!
State/province [94]
0
0
Aarau
Query!
Country [95]
0
0
Switzerland
Query!
State/province [95]
0
0
Locarno
Query!
Country [96]
0
0
Switzerland
Query!
State/province [96]
0
0
Sursee
Query!
Country [97]
0
0
Taiwan
Query!
State/province [97]
0
0
TAIWANwan
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Berkshire
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Newcastle Upon Tyne
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
London
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Enthuse M1C is a large phase III clinical trial studying the safety and efficacy of ZD4054
(Zibotentan) in combination with docetaxel (Taxotere) in patients with metastatic hormone
resistant prostate cancer (HRPC).
This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can
further improve survival compared with docetaxel alone.
ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread
by blocking Endothelin A receptor activity. This trial will look at the effects of ZD4054
(Zibotentan) in hormone resistant prostate cancer patients with bone metastases compared with
docetaxel.
All patients participating in this clinical trial will receive docetaxel chemotherapy, which
is a commonly used chemotherapy to treat prostate cancer in addition to other existing
prostate cancer therapies.
Half the patients will receive ZD4054 (Zibotentan), and half the patients will receive
placebo in addition to docetaxel and other prostate cancer therapy. By participating in this
trial there is a 50% chance that patients will receive an agent that may further slow the
progression of the tumour.
No patients will be deprived of standard prostate cancer therapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00617669
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Karim Fizazi, MD, PhD
Query!
Address
0
0
Gustave Roussy, Cancer Campus, Grand Paris
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00617669
Download to PDF